28105015|t|The Potassium Channel KCa3.1 Represents a Valid Pharmacological Target for Astrogliosis-Induced Neuronal Impairment in a Mouse Model of Alzheimer's Disease.
28105015|a|Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline of cognitive function. Astrogliosis plays a critical role in AD by instigating neuroinflammation, which leads ultimately to cognition decline. We previously showed that the intermediate-conductance Ca2+-activated potassium channel (KCa3.1) is involved in astrogliosis-induced by TGF-beta in vitro. In the present study, we investigated the contribution of KCa3.1 channels to astrogliosis-mediated neuroinflammation, using TgAPP/PS1 mice as a model for AD. We found that KCa3.1 expression was increased in reactive astrocytes as well as in neurons in the brains of both TgAPP/PS1 mice and AD patients. Pharmacological blockade of KCa3.1 significantly reduced astrogliosis, microglial activation, neuronal loss, and memory deficits. KCa3.1 blockade inhibited astrocyte activation and reduced brain levels of IL-1beta, TNF-alpha, iNOS, and COX-2. Furthermore, we used primary co-cultures of cortical neurons and astrocytes to demonstrate an important role for KCa3.1 in the process of astrogliosis-induced neuroinflammatory responses during amyloid-beta (Abeta)-induced neuronal loss. KCa3.1 was found to be involved in the Abeta-induced activated biochemical profile of reactive astrocytes, which included activation of JNK MAPK and production of reactive oxygen species. Pharmacological blockade of KCa3.1 attenuated Abeta-induced reactive astrocytes and indirect, astrogliosis-mediated damage to neurons. Our data clearly indicate a role for astrogliosis in AD pathogenesis and suggest that KCa3.1 inhibition might represent a good therapeutic target for the treatment of AD. Highlights: (1) Blockade of KCa3.1 in APP/PS1 transgenic mice attenuated astrogliosis and neuron loss, and an attenuation of memory deficits. (2) Blockade of KCa3.1 attenuated Abeta-induced indirect, astrogliosis-mediated damage to neurons in vitro via activation of JNK and ROS.
28105015	22	28	KCa3.1	Gene	16534
28105015	75	87	Astrogliosis	Disease	MESH:D005911
28105015	96	115	Neuronal Impairment	Disease	MESH:D009410
28105015	121	126	Mouse	Species	10090
28105015	136	155	Alzheimer's Disease	Disease	MESH:D000544
28105015	157	176	Alzheimer's disease	Disease	MESH:D000544
28105015	178	180	AD	Disease	MESH:D000544
28105015	187	213	neurodegenerative disorder	Disease	MESH:D019636
28105015	243	272	decline of cognitive function	Disease	MESH:D003072
28105015	274	286	Astrogliosis	Disease	MESH:D005911
28105015	312	314	AD	Disease	MESH:D000544
28105015	330	347	neuroinflammation	Disease	MESH:D000090862
28105015	375	392	cognition decline	Disease	MESH:D003072
28105015	483	489	KCa3.1	Gene	16534
28105015	506	518	astrogliosis	Disease	MESH:D005911
28105015	530	538	TGF-beta	Gene	21803
28105015	626	638	astrogliosis	Disease	MESH:D005911
28105015	648	665	neuroinflammation	Disease	MESH:D000090862
28105015	679	682	PS1	Gene	19164
28105015	683	687	mice	Species	10090
28105015	703	705	AD	Disease	MESH:D000544
28105015	721	727	KCa3.1	Gene	16534
28105015	826	829	PS1	Gene	19164
28105015	830	834	mice	Species	10090
28105015	839	841	AD	Disease	MESH:D000544
28105015	842	850	patients	Species	9606
28105015	880	886	KCa3.1	Gene	16534
28105015	909	921	astrogliosis	Disease	MESH:D005911
28105015	946	959	neuronal loss	Disease	MESH:D009410
28105015	965	980	memory deficits	Disease	MESH:D008569
28105015	982	988	KCa3.1	Gene	16534
28105015	1057	1065	IL-1beta	Gene	16176
28105015	1067	1076	TNF-alpha	Gene	21926
28105015	1078	1082	iNOS	Gene	18126
28105015	1088	1093	COX-2	Gene	17709
28105015	1208	1214	KCa3.1	Gene	16534
28105015	1233	1245	astrogliosis	Disease	MESH:D005911
28105015	1254	1271	neuroinflammatory	Disease	MESH:D000090862
28105015	1303	1308	Abeta	Gene	11820
28105015	1318	1331	neuronal loss	Disease	MESH:D009410
28105015	1333	1339	KCa3.1	Gene	16534
28105015	1372	1377	Abeta	Gene	11820
28105015	1496	1519	reactive oxygen species	Chemical	MESH:D017382
28105015	1549	1555	KCa3.1	Gene	16534
28105015	1567	1572	Abeta	Gene	11820
28105015	1615	1627	astrogliosis	Disease	MESH:D005911
28105015	1693	1705	astrogliosis	Disease	MESH:D005911
28105015	1709	1711	AD	Disease	MESH:D000544
28105015	1742	1748	KCa3.1	Gene	16534
28105015	1823	1825	AD	Disease	MESH:D000544
28105015	1855	1861	KCa3.1	Gene	16534
28105015	1869	1872	PS1	Gene	19164
28105015	1884	1888	mice	Species	10090
28105015	1900	1912	astrogliosis	Disease	MESH:D005911
28105015	1917	1928	neuron loss	Disease	MESH:D009410
28105015	1952	1967	memory deficits	Disease	MESH:D008569
28105015	1985	1991	KCa3.1	Gene	16534
28105015	2003	2008	Abeta	Gene	11820
28105015	2027	2039	astrogliosis	Disease	MESH:D005911
28105015	2094	2097	JNK	Gene	26419
28105015	2102	2105	ROS	Chemical	MESH:D017382
28105015	Positive_Correlation	MESH:D005911	21803
28105015	Negative_Correlation	16176	16534
28105015	Association	MESH:D017382	16534
28105015	Positive_Correlation	MESH:D009410	11820
28105015	Association	MESH:D000544	16534
28105015	Negative_Correlation	16534	18126
28105015	Association	MESH:D000090862	16534
28105015	Association	16534	26419
28105015	Association	MESH:D005911	16534
28105015	Negative_Correlation	16534	17709
28105015	Association	16534	21803
28105015	Negative_Correlation	MESH:D008569	16534
28105015	Negative_Correlation	16534	21926
28105015	Positive_Correlation	MESH:D017382	11820
28105015	Association	MESH:D009410	16534
28105015	Association	11820	16534

